Indication: Head and Neck Cancer
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
Squamous Cell Carcinoma
Sub-indication: H&N cancer with HRAS mutations
Line of Therapy: 2nd line therapy after failed platinum
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Kura Oncology, Inc.
Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org